Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Capital Expenditures (2016 - 2026)

Gyre Therapeutics has reported Capital Expenditures over the past 14 years, most recently at $144000.0 for Q4 2025.

Quarterly Capital Expenditures rose 321.54% to $144000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 48.6% year-over-year, with the annual reading at $1.2 million for FY2025, 48.6% down from the prior year.
Capital Expenditures was $144000.0 for Q4 2025 at Gyre Therapeutics, down from $668000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $2.5 million in Q2 2023 and troughed at -$65000.0 in Q4 2024.
The 4-year median for Capital Expenditures is $668000.0 (2025), against an average of $962615.4.
Year-over-year, Capital Expenditures plummeted 102.8% in 2024 and then surged 321.54% in 2025.
A 4-year view of Capital Expenditures shows it stood at $492000.0 in 2021, then soared by 372.36% to $2.3 million in 2023, then tumbled by 102.8% to -$65000.0 in 2024, then surged by 321.54% to $144000.0 in 2025.
Per Business Quant, the three most recent readings for GYRE's Capital Expenditures are $144000.0 (Q4 2025), $668000.0 (Q3 2025), and $256000.0 (Q2 2025).